Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the announcement of “unprecedented” ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

in addition to treatment, be an effective way to delay or prevent the onset of depressive disorders. Preventing or delaying these disorders may contribute to the further reduction of the disease ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

The criteria for diagnosing SAD are similar to diagnosing major ... disorders. On average, SAD will last about five months of ...